



ABN 58 008 130 336
Suite 605 Level 6
50 Clarence Street
Sydney NSW 2000
Phone: +61 2 9299 9580
Fax: +61 2 9299 9501

13 December 2013

NOTICE GIVEN UNDER SECTION 708A(5) OF THE CORPORATIONS ACT

This notice is given by BioProspect Limited ("the Company") (ASX: **BPO**) under section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (the "Corporations Act") in relation to an issue of 25,000,000 fully paid ordinary shares in the Company to Heartlink Limited as payment for the grant of an option and notified to the market by an issue of an Appendix 3B on 11 December 2013.

- The abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- As at the date of the notice the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company.
- As at the date of this notice, the Company has complied with section 674 of the Act
- As at the date of this notice there is no excluded information" (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

For further information please contact:

Robert Lees
Company Secretary
Phone: +61 2 9299 9580